background
epsteinbarr
viru
ebv
ubiquit
herpesviru
kaposi
sarcomaassoci
herpesviru
kshv
restrict
seropreval
virus
associ
malign
increas
frequenc
individu
coinfect
human
immunodefici
viru
type
method
obtain
overview
humor
immun
respons
virus
gener
protein
array
display
ebv
kshv
polypeptid
purifi
yeast
antibodi
respons
ebv
kshv
examin
plasma
healthi
volunt
patient
b
cell
lymphoma
aidsrel
kaposi
sarcoma
lymphoma
result
addit
commonli
studi
antigen
igg
respons
frequent
detect
tegument
protein
kshv
ebv
bbrf
ebv
earli
lytic
protein
ebv
protein
particularli
well
recogn
plasma
iga
intens
igg
respons
ebv
antigen
occur
patient
clear
correl
observ
viral
dna
load
plasma
antibodi
profil
conclus
protein
array
provid
sensit
platform
global
screen
identifi
new
frequent
recogn
viral
antigen
reveal
broader
humor
respons
ebv
compar
kshv
patient
background
epsteinbarr
viru
ebv
ubiquit
herpesviru
kaposi
sarcomaassoci
herpesviru
kshv
restrict
seropreval
virus
associ
malign
increas
frequenc
individu
coinfect
human
immunodefici
viru
type
method
obtain
overview
humor
immun
respons
virus
gener
protein
array
display
ebv
kshv
polypeptid
purifi
yeast
antibodi
respons
ebv
kshv
examin
plasma
healthi
volunt
patient
b
cell
lymphoma
aidsrel
kaposi
sarcoma
lymphoma
result
addit
commonli
studi
antigen
igg
respons
frequent
detect
tegument
protein
kshv
ebv
bbrf
ebv
earli
lytic
protein
ebv
protein
particularli
well
recogn
plasma
iga
intens
igg
respons
ebv
antigen
occur
patient
clear
correl
observ
viral
dna
load
plasma
antibodi
profil
conclus
protein
array
provid
sensit
platform
global
screen
identifi
new
frequent
recogn
viral
antigen
reveal
broader
humor
respons
ebv
compar
kshv
patient
epsteinbarr
viru
ebv
kaposi
sarcomaassoci
herpesviru
kshv
human
herpesvirus
differ
dramat
geograph
preval
ebv
seroposit
healthi
popul
worldwid
kshv
seroposit
low
unit
state
canada
europ
intermedi
itali
mediterranean
high
subsaharan
africa
seropreval
kshv
increas
individu
coinfect
human
immunodefici
viru
unit
state
europ
men
sex
men
primari
infect
ebv
caus
infecti
mononucleosi
ebv
kshv
associ
human
cancer
ebv
associ
nasopharyng
carcinoma
african
burkitt
lymphoma
subset
hodgkin
lymphoma
aidsrel
lymphoma
gastric
carcinoma
peripher
cell
lymphoma
posttranspl
lymphoprolif
diseas
immunodefici
kshv
associ
kaposi
sarcoma
primari
effus
lymphoma
multicentr
castleman
diseas
immunosuppress
impos
concurr
infect
transplant
regimen
increas
incid
virusassoci
cancer
dna
genom
ebv
kshv
encod
estim
protein
respect
degre
protein
express
differ
depend
stage
viral
life
cycl
vivo
reservoir
ebv
latent
infect
rest
memori
b
cell
either
ebv
protein
express
transient
express
protein
express
latenc
protein
ebnalp
detect
peripher
blood
b
cell
shortli
primari
infect
b
cell
tonsillar
tissu
lytic
replic
express
ebv
lytic
protein
take
place
plasma
cell
epitheli
cell
less
known
vivo
persist
kshv
b
cell
form
reservoir
latent
kshv
infect
differenti
cell
also
trigger
lytic
kshv
induct
kshv
endotheli
b
cell
tumor
express
lana
vcyclin
vflip
latenc
protein
also
detect
latenc
protein
primaryeffus
lymphoma
cell
addit
small
percentag
tumor
cell
express
lytic
cycl
protein
viral
gprotein
coupl
receptor
vgpcr
suggest
kshv
lytic
infect
may
contribut
tumorigen
phenotyp
transcript
profil
array
develop
examin
genomewid
express
ebv
kshv
howev
humor
immun
respons
ebv
kshv
protein
predominantli
measur
use
virusinfect
cell
line
enzymelink
immunosorb
assay
incorpor
select
viral
protein
although
assay
proven
valuabl
diagnost
epidemiolog
studi
provid
complet
pictur
full
repertoir
antibodi
respons
gener
ebv
kshv
infect
highthroughput
technolog
allow
clone
express
entir
pathogen
proteom
use
technolog
gener
proteom
microarray
ebv
kshv
array
allow
us
compar
global
humor
immun
respons
ebv
vs
kshv
patient
sampl
within
assay
ebv
kshv
open
read
frame
orf
clone
express
previous
describ
briefli
open
read
frame
polymeras
chain
reaction
pcr
amplifi
use
primer
base
genbank
sequenc
bacteri
artifici
chromosom
plasmid
akata
bxi
ebv
kshv
use
templat
gift
l
huttfletch
sj
gao
pcr
product
clone
vector
orf
repres
differ
viru
strain
amplifi
directli
clinic
sampl
cell
line
protein
contain
extens
repeat
limit
express
yeast
eg
lana
amplifi
ntermin
ctermin
fragment
escherichia
coli
bacteria
transform
reaction
product
dna
prepar
sequenc
verif
correct
orfcontain
plasmid
dna
move
yeast
destin
vector
pegha
deriv
yeast
glutathion
stransferas
gst
vector
pegh
yeast
cultur
induc
galactos
gst
fusion
protein
isol
purifi
glutathion
bead
one
hundr
seventyfour
appropri
size
ebv
kshv
protein
tabl
avail
onlin
success
purifi
base
immunoblot
analysi
use
antigst
antibodi
print
use
contact
printer
biorad
duplic
modifi
glass
full
moon
biosystem
microscop
slide
along
control
slide
spot
ebv
kshv
protein
control
protein
tabl
avail
onlin
blank
spot
control
use
orient
detect
nonspecif
interact
protein
gst
fusion
partner
protein
array
store
plasma
healthi
blood
donor
patient
follicular
b
cell
lymphoma
without
aidsrel
lymphoma
arl
aid
kaposi
sarcoma
obtain
written
inform
consent
accord
declar
helsinki
approv
john
hopkin
institut
review
board
plasma
separ
peripher
blood
collect
standard
edta
acid
citrat
dextros
tube
store
protein
array
preincub
ml
superblock
pierc
plu
bovin
serum
albumen
bsa
overnight
slide
assembl
modul
incub
plasma
ul
dilut
phosphat
buffer
salin
pb
plu
bsa
hour
room
temperatur
slide
wash
prewarm
pb
pbst
incub
secondari
antihuman
igg
iga
antibodi
sigma
jackson
respect
dilut
pb
plu
bsa
hour
room
temperatur
slide
wash
prewarm
pbst
prewarm
distil
water
dri
scan
analyz
genepix
pro
softwar
molecular
devic
softwar
genepix
pro
use
obtain
median
foreground
background
intens
spot
raw
intens
spot
defin
ratio
foreground
background
median
intens
blank
spot
protein
chip
raw
intens
distribut
spot
mean
valu
approxim
assum
raw
intens
distribut
blank
spot
across
microarray
standard
protein
signal
r
z
zscore
spot
raw
intens
spot
r
mean
valu
standard
deviat
respect
blank
spot
microarray
protein
duplic
spot
identifi
hit
defin
protein
zscore
spot
sd
cutoff
compar
appear
frequenc
individu
antigen
hivk
patient
vs
lymphoma
healthi
normal
enrich
score
reflect
es
f
ks
f
adopt
binomin
probabl
calcul
signific
comparison
p
probabl
protein
hit
least
k
hivk
patient
n
total
number
hivk
patient
f
frequenc
protein
comparison
group
either
lymphoma
healthi
normal
protein
select
signific
biomark
hiv
ks
patient
least
frequenc
hiv
ks
patient
enrich
score
es
larger
p
valu
less
ebv
kshv
dna
plasma
detect
previous
describ
viral
dna
level
determin
realtim
quantit
pcr
use
primer
kshv
bamhiw
primer
ebv
control
construct
addit
viral
dna
serum
healthi
donor
standard
curv
duplic
serial
dilut
plasmid
dna
includ
target
sequenc
copi
run
parallel
analysi
systemat
compar
ebv
kshv
antibodi
respons
util
proteom
array
display
viru
protein
plu
control
print
qualiti
quantiti
immobil
protein
chip
monitor
use
antigst
antibodi
follow
secondari
antibodi
figur
preliminari
analys
array
contain
ebv
kshv
orf
reveal
plasma
dilut
gave
signal
array
readili
detect
antihuman
igg
posit
signal
set
one
sd
background
section
array
illustr
posit
control
signal
shown
figur
tegument
protein
wide
examin
antigen
encod
latenc
lana
protein
gold
standard
kshv
serolog
studi
central
region
lana
contain
repeat
sequenc
limit
effect
express
protein
yeast
nterminu
cterminu
lana
therefor
express
separ
present
array
lana
cterminu
recogn
frequent
nterminu
vs
posit
plasma
consist
peptid
map
studi
found
sera
react
peptid
map
lana
cterminu
nterminu
median
number
kshv
antigen
recogn
lanaposit
hiv
ks
plasma
serum
dilut
analysi
ebv
protein
recogn
assay
plasma
sampl
reveal
differ
pictur
ebv
ubiquit
viru
ebv
protein
array
recogn
use
plasma
healthi
donor
hiv
lymphoma
patient
hiv
ks
patient
figur
median
number
ebv
protein
recogn
serum
dilut
plasma
healthi
donor
lymphoma
patient
hiv
ks
patient
respect
ninetyon
percent
plasma
specimen
test
react
carboxi
terminu
react
combin
dilut
singl
plasma
specimen
lymphoma
patient
whose
plasma
recogn
ebv
antigen
differ
normal
hiv
lymphoma
popul
hiv
ks
popul
lay
individu
antigen
recogn
rather
heighten
antigen
respons
rang
ebv
protein
illustr
increas
median
number
antigen
detect
plasma
dilut
seen
hiv
ks
sampl
vs
median
number
plasma
healthi
donor
lymphoma
patient
respect
antigen
statist
signific
differ
appear
healthi
donor
hiv
ks
patient
dilut
shown
figur
also
includ
data
hivneg
lymphoma
patient
compar
purpos
capsid
antigen
previous
advoc
serolog
marker
nasopharyng
carcinoma
diagnosi
two
subtyp
ebv
type
type
also
call
b
origin
defin
basi
differ
gene
set
sera
show
discord
respons
protein
either
differ
sensit
detect
vs
recognit
protein
like
individu
infect
ebv
subtyp
note
discord
sera
preferenti
recognit
type
consist
greater
preval
type
ebv
clinic
sampl
unit
state
posit
protein
would
repres
recognit
common
epitop
reflect
concurr
infect
viru
subtyp
contrast
antibodi
respons
kshv
protein
profil
antibodi
respons
ebv
protein
plasma
sampl
similar
ks
lymphomacarri
hivposit
popul
figur
signific
differ
either
intens
posit
signal
number
antigen
recogn
serum
dilut
thu
presenc
kshvassoci
diseas
appear
impact
humor
respons
ebv
antigen
set
concurr
infect
broader
antigen
respons
ebv
compar
kshv
strike
exon
ebv
bamhiw
encod
amino
acid
form
part
ebnalp
protein
protein
encod
entir
ebv
bamhiw
orf
ebnalp
protein
print
array
note
specimen
recogn
ebnalp
also
recogn
protein
encod
impli
common
amino
acid
contribut
significantli
antibodi
recognit
ebnalp
ebv
kshv
dna
detect
infrequ
serum
plasma
healthi
individu
increas
preval
cancer
patient
individu
consist
correl
ebv
kshv
dna
level
serum
plasma
antibodi
titer
viral
protein
appar
see
global
antibodi
respons
detect
array
would
provid
addit
insight
examin
kshv
ebv
dna
level
plasma
hivposit
ks
patient
see
figur
plasma
copi
number
kshv
ebv
dna
measur
realtim
quantit
pcr
use
previous
publish
primer
comparison
dna
copi
number
antibodi
respons
reveal
obviou
correl
either
kshv
ebv
figur
howev
sampl
highest
kshv
dna
copi
number
copi
recogn
either
lytic
protein
wherea
sampl
copi
recogn
antigen
two
sampl
insuffici
allow
conclus
drawn
observ
rais
possibl
inadequ
antibodi
product
may
contribut
robust
kshv
replic
detect
individu
iga
respons
ebv
viral
capsid
antigen
long
use
diagnost
tool
nasopharyng
carcinoma
addit
nasopharyng
carcinoma
iga
respons
vca
frequent
elev
lymphoma
patient
individu
posit
iga
respons
ebv
protein
examin
dilut
hivposit
ks
patient
healthi
individu
hivposit
lymphoma
patient
seven
ebv
antigen
consist
recogn
iga
across
patient
group
name
helicas
viral
uracil
dna
glycoslyas
earli
protein
tegument
protein
latenc
membran
protein
figur
intens
iga
respons
detect
appear
recogn
even
readili
iga
igg
normal
hivposit
ks
plasma
test
recogn
dilut
wherea
sampl
recognit
igg
even
dilut
howev
iga
respons
function
equival
protein
kshv
lana
differ
hivposit
ks
plasma
sampl
igg
respons
lana
dilut
iga
respons
dilut
data
shown
previou
studi
iga
antibodi
kshv
lana
detect
saliva
serum
comparison
igg
iga
respons
plasma
healthi
donor
also
reveal
differenti
respons
certain
ebv
protein
normal
sera
iga
respons
dilut
viral
tegument
protein
latenc
membran
protein
contrast
even
dilut
igg
respons
detect
plasma
sampl
iga
respons
particularli
interest
immun
modul
impact
local
immun
escap
ebvinfect
cell
test
ebv
kshv
reli
assay
immunofluoresc
stain
western
blot
infect
cell
assay
use
individu
viral
protein
also
describ
howev
absenc
global
comparison
protein
immunogen
inadequ
inform
base
choic
antigen
incorpor
assay
ebv
latenc
protein
kshv
lana
latenc
lytic
protein
wide
use
antigen
antigen
also
frequent
detect
array
protein
array
screen
also
identifi
ebv
tegument
protein
fgarat
small
capsid
protein
earli
protein
kshv
tegument
protein
lytic
viral
protein
particularli
well
recogn
igg
screen
also
identifi
ebv
lytic
protein
well
recogn
iga
note
ebv
kshv
protein
array
express
yeast
machineri
mammalian
cell
complex
glycosyl
therefor
like
assay
underestim
immunolog
respons
glycosyl
viral
antigen
ebv
envelop
glycoprotein
kshv
global
array
analys
reveal
stark
contrast
antibodi
respons
ebv
kshv
patient
multipl
ebv
protein
consist
recogn
plasma
igg
dilut
examin
wherea
lana
protein
kshv
detect
consist
even
patient
ks
differ
carri
serum
iga
respons
latenc
ebv
protein
lytic
protein
detect
major
sera
kshv
antigen
detect
iga
lana
seen
rare
observ
differ
may
reflect
biolog
vivo
persist
virus
latent
infect
b
cell
virus
secret
saliva
howev
ebv
routin
detect
circul
latent
infect
b
cell
healthi
seroposit
individu
wherea
detect
kshv
blood
rare
preferenti
abil
detect
serum
iga
respons
ebv
vs
kshv
protein
array
may
also
relat
vivo
infect
mucos
epitheli
cell
ebv
frequent
observ
antigen
latenc
protein
lytic
replic
protein
known
express
epitheli
cell
kshv
infect
endotheli
cell
well
b
cell
contribut
endotheli
cell
vivo
viral
persist
well
understood
protein
array
describ
provid
highli
sensit
platform
plasma
titer
convent
anticompl
immunofluoresc
assay
titer
greater
array
assay
data
shown
assay
show
specif
igg
respons
kshv
protein
detect
sera
hivposit
individu
diagnosi
ks
lymphoma
detect
panel
hivneg
lymphoma
patient
healthi
normal
result
along
comparison
ebv
kshv
respons
hivposit
sampl
indic
crossreact
homolog
protein
encod
ebv
kshv
confound
factor
array
provid
new
platform
investig
contribut
humor
immun
respons
patient
ebvand
kshvassoci
patholog
supplementari
materi
avail
journal
infecti
diseas
onlin
http
wwwoxfordjournalsorgourjournalsjid
supplementari
materi
consist
data
provid
author
publish
benefit
reader
post
materi
copyedit
content
supplementari
data
sole
respons
author
question
messag
regard
error
address
author
figur
iga
respons
ebv
protein
plasma
specimen
ks
patient
aidsrel
lymphoma
patient
healthi
individu
incub
protein
array
dilut
upper
panel
heat
map
show
respons
detect
antihuman
iga
sd
cutoff
lower
panel
number
antigen
recogn
sampl
financi
support
work
support
public
health
servic
grant
nation
cancer
institut
nation
institut
health
h
h
h
z
g
h
cancer
center
core
grant
william
nelson
potenti
conflict
interest
author
report
conflict
